For example, benefits of cetuximab and panitumumab in colorectal cancer and benefits of the EGFR tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib in NSCLC are respectively associated with presence vs absence of KRAS and EGFR mutations. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.